Source-grounded facts extracted from Mirum Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mirum Pharmaceuticals, Inc. incurred convertible notes of $690.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.
“On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032”
Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $159.9 million. Guidance raised.
“in such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update – Q1 2026 net product sales of $159.9 million – 2026 net product sales guidance increased to $660 to $680 million – Volixibat VISTAS Phase 2b study met primary endpoint – Brelovitug Phase 2b portion of AZURE-1 study met”
Mirum Pharmaceuticals, Inc. completed an acquisition involving Bluejay Therapeutics, Inc. for up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock (closed 2026-01-23).
“of the Mergers, the Company acquired Target’s net cash of approximately $56.6 million and paid or will pay to the holders of Target’s securities up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock, subject to the Company’s receipt of deliverables that are a condition to payment and deduction to satisfy applicable”
Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.
“such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and”
Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).
“On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.